This company has been marked as potentially delisted and may not be actively trading. Cyclacel Pharmaceuticals (CYCCP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendFDA EventsHeadlinesTrendsBuy This Stock CYCCP vs. ATNFW, SXTPW, DRTSW, APLMW, BCTXW, CDIOW, CELUW, CEROW, CINGW, and CLNNWShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), CERo Therapeutics (CEROW), Cingulate (CINGW), and Clene (CLNNW). These companies are all part of the "biotechnology" industry. Cyclacel Pharmaceuticals vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Celularity CERo Therapeutics Cingulate Clene 180 Life Sciences (NASDAQ:ATNFW) and Cyclacel Pharmaceuticals (NASDAQ:CYCCP) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Does the media refer more to ATNFW or CYCCP? In the previous week, 180 Life Sciences had 2 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 2 mentions for 180 Life Sciences and 0 mentions for Cyclacel Pharmaceuticals. 180 Life Sciences' average media sentiment score of 0.48 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Neutral Cyclacel Pharmaceuticals Neutral Which has preferable earnings and valuation, ATNFW or CYCCP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ACyclacel PharmaceuticalsN/AN/AN/AN/AN/A Is ATNFW or CYCCP more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Cyclacel Pharmaceuticals N/A N/A N/A Summary180 Life Sciences beats Cyclacel Pharmaceuticals on 2 of the 2 factors compared between the two stocks. Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCCP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCCP vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$134.47M$5.47B$9.53BDividend Yield0.12%3.74%4.74%4.08%P/E RatioN/A3.7828.6723.80Price / SalesN/A4,246.60422.2688.08Price / CashN/A13.1935.4557.96Price / BookN/A39.388.275.55Net IncomeN/A-$90.99M$3.24B$259.03M Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCPCyclacel PharmaceuticalsN/A$4.05-23.6%N/A-61.4%$0.00N/A0.0012ATNFW180 Life SciencesN/A$0.01+26.0%N/A+18.6%$0.00N/A0.007News CoverageGap DownHigh Trading VolumeSXTPW60 Degrees PharmaceuticalsN/A$0.05+31.8%N/A-13.9%$0.00$665.45K0.002Gap UpDRTSWAlpha Tau MedicalN/A$0.24+2.6%N/A+35.6%$0.00N/A0.0080Positive NewsGap DownAPLMWApollomicsN/A$0.03+6.2%N/A+228.0%$0.00N/A0.0059Positive NewsGap UpBCTXWBriaCell TherapeuticsN/A$0.05-2.8%N/A-82.0%$0.00N/A0.008Short Interest ↑Gap DownCDIOWCardio DiagnosticsN/A$0.01flatN/A-70.4%$0.00$19.90K0.007Positive NewsShort Interest ↑Gap DownCELUWCelularityN/A$0.06+19.8%N/AN/A$0.00$54.22M0.00220News CoveragePositive NewsGap DownHigh Trading VolumeCEROWCERo TherapeuticsN/A$0.02flatN/A-41.3%$0.00N/A0.008Positive NewsShort Interest ↑Gap DownCINGWCingulateN/A$0.12+0.6%N/A+817.4%$0.00N/A0.0020Positive NewsGap UpCLNNWCleneN/A$0.04+46.7%N/A-2.0%$0.00$350K0.00100Positive NewsGap Up Related Companies and Tools Related Companies 180 Life Sciences Competitors 60 Degrees Pharmaceuticals Competitors Alpha Tau Medical Competitors Apollomics Competitors BriaCell Therapeutics Competitors Cardio Diagnostics Competitors Celularity Competitors CERo Therapeutics Competitors Cingulate Competitors Clene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCCP) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCCP Stock Alerts